Immunocore Holdings plc Income Tax Expense
Immunocore Holdings plc (IMCR) reported Income Tax Expense of $294.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-06
- Immunocore Holdings plc income tax expense (benefit) for the quarter ending 2026-06-30 was $294.00K, a 51.49% decline year-over-year.
- Immunocore Holdings plc income tax expense (benefit) for the quarter ending 2026-03-31 was $301.00K, a 71.63% decline year-over-year.
- Immunocore Holdings plc income tax expense (benefit) for the quarter ending 2025-12-31 was $14.27M.
- Immunocore Holdings plc income tax expense (benefit) for the quarter ending 2025-09-30 was $481.00K.
- Immunocore Holdings plc income tax expense (benefit) for fiscal 2025 was $16.41M.
- Immunocore Holdings plc income tax expense (benefit) for fiscal 2024 was -$1.85M.
- Immunocore Holdings plc income tax expense (benefit) for fiscal 2023 was -$5.60M, a 148.05% decline from fiscal 2022.
- Immunocore Holdings plc income tax expense (benefit) for fiscal 2022 was $11.66M, a 7673.33% increase from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $294.00K 10-Q · filed 2026-08-06 | $595.00K 10-Q · filed 2026-08-06 | $14.86M derived: sum of 3 quarters · filed 2026-08-06 | $15.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $301.00K 10-Q · filed 2026-05-06 | $14.57M derived: sum of 2 quarters · filed 2026-05-06 | $15.05M derived: sum of 3 quarters · filed 2026-05-06 | $15.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $14.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $14.75M derived: sum of 2 quarters · filed 2026-02-25 | $15.35M derived: sum of 3 quarters · filed 2026-08-06 | $16.41M 10-K · filed 2026-02-25 |
| 2025-09-30 | $481.00K 10-Q · filed 2025-11-06 | $1.09M derived: sum of 2 quarters · filed 2026-08-06 | $2.15M 10-Q · filed 2025-11-06 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $606.00K 10-Q · filed 2026-08-06 | $1.67M 10-Q · filed 2026-08-06 | $617.00K derived: sum of 3 quarters · filed 2026-08-06 | -$2.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.06M 10-Q · filed 2026-05-06 | $11.00K derived: sum of 2 quarters · filed 2026-05-06 | -$2.63M derived: sum of 3 quarters · filed 2026-05-06 | -$1.15M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$3.69M derived: sum of 2 quarters · filed 2026-02-25 | -$2.21M derived: sum of 3 quarters · filed 2026-02-25 | -$1.85M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$2.64M 10-Q · filed 2025-11-06 | -$1.16M derived: sum of 2 quarters · filed 2025-11-06 | -$800.00K 10-Q · filed 2025-11-06 | -$6.71M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.49M 10-Q · filed 2025-08-07 | $1.84M 10-Q · filed 2025-08-07 | -$4.07M derived: sum of 3 quarters · filed 2026-02-25 | -$4.24M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $357.00K 10-Q · filed 2025-05-07 | -$5.55M derived: sum of 2 quarters · filed 2026-02-25 | -$5.73M derived: sum of 3 quarters · filed 2026-02-25 | -$5.54M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$6.09M derived: sum of 2 quarters · filed 2026-02-25 | -$5.89M derived: sum of 3 quarters · filed 2026-02-25 | -$5.60M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$175.00K 10-Q · filed 2024-11-06 | $16.00K derived: sum of 2 quarters · filed 2024-11-06 | $308.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $191.00K 10-Q · filed 2024-08-08 | $484.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $293.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $11.66M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $150.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |